Oculis adds Vanessa Huang and Dr. Sylvia He to Board along with closing $57m Series C financing co-led by BVCF and Hyfinity Investments

– SWITZERLAND, Lausanne –   Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, today announced that it has closed an oversubscribed US$57 million Series C financing round co-led by BVCF Management and Hyfinity Investments, along with VI Partners and Wille AG joining the existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg among other existing investors.…